TABLE 1.

Studies of valbenazine

STUDY	PHASE	STUDY DESIGN	DURATION	n	DRUG DOSE
KINECT8	II	Randomized, double-blind, placebo-controlled, parallel-group	6 weeks	109	50mg or 100mg
KINECT extension9	II	Open-label extension of KINECT	6 weeks	80	50mg
KINECT 210	II	Randomized, double-blind, placebo-controlled, parallel-group	6 weeks	102	25–75mg
KINECT 311	III	Randomized, double-blind, placebo-controlled, parallel-group	6 weeks	234	40mg or 80mg
KINECT 3 extension12	III	Open-label extension of KINECT 3 with washout period	42 weeks followed by 4-week washout period	198	40mg or 80mg
KINECT 413	III	Open-label	48 weeks	168	2 varying doses (not specified)